August 26, 2024
Tryptamine Therapeutics (ASX:TYP) completes pivotal Phase 1b trial for psilocin-based therapy
Tryptamine Therapeutics has successfully completed its Phase 1b trial for TRP-8803, marking a significant step forward in the development of its innovative psilocin-based therapy.